Clinical trials: Oral Chemotherapy
Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer
Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses x-rays to damage tumor cells.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Radiation Toxicity
- Trial name
- NCT00003251
- Testing
- amifostine trihydrate, cisplatin, paclitaxel
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Illinois Chicago
Salivary Gland Cancer
Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study
Cisplatin plus weekly docetaxel as first-line chemotherapy in metastatic salivary gland cancer patients : a multicenter phase II study
- Trial name
- NCT05008237
- Testing
- docetaxel plus Cisplatin
- Where
- South Korea
- Volunteers
- 42 people
- Sponsor
- Samsung Medical Center
Lung Cancer, Squamous Cell Carcinoma of the Lung
Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma
Treatment of locally advanced and metastatic squamous cell carcinoma of the lung involves the use of chemotherapy as the therapeutic mainstay.
- Conditions
- Lung Cancer, Squamous Cell Carcinoma of the Lung, Locally Advanced and Metastatic Squamous Cell Carcinoma of the Lung
- Trial name
- NCT01947062
- Testing
- Intravenous Cisplatin & etoposide, Intravenous Cisplatin & etoposide along with oral cyclophosphamide
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Swami Rama Cancer Hospital and Research Institute
Mucositis Oral
Low-level Laser Therapy in the Prevention of Chemotherapy-induced Mucositis in Children and Young Adults
To assess the efficacy of preventive Low-Level Laser Therapy (LLLT) for reducing the incidence of WHO's grade 3-4 oral mucositis in children and young adults receiving chemotherapy regimens associated with a high rate of…
- Trial name
- MUCILA (NCT03983369)
- Testing
- Low-Level Laser Therapy
- Where
- 5 sites in France
- Volunteers
- 315 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Type 2 Diabetes Mellitus
Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of TAK-875 in Asia Pacific adults with type 2 diabetes mellitus (T2DM).
- Trial name
- GRAND-307 (NCT01647542)
- Testing
- TAK-875
- Where
- 51 sites in Australia, China and 3 more
- Volunteers
- 393 people
- Sponsor
- Takeda
Lymphoma
Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003114
- Testing
- filgrastim, cyclophosphamide, etoposide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Case Comprehensive Cancer Center
Gastroesophageal Reflux
Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)
The purpose of this study is to determine the effect of vonoprazan compared to esomeprazole for preventing heartburn symptoms over a 4-week treatment period in participants who have a partial response to treatment with…
- Trial name
- NCT02743949
- Testing
- Vonoprazan, Esomeprazole
- Where
- 39 sites in Belgium, Bulgaria and 4 more
- Volunteers
- 256 people
- Sponsor
- Takeda
Advanced Solid Tumors, Relapsed/Refractory Lymphoma
Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function
The purpose of this study is to evaluate the effect of moderate or severe hepatic impairment on the single-dose pharmacokinetics of alisertib in adult participants with cancer.
- Trial name
- NCT02214147
- Testing
- Alisertib
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Cancer
Medico-economic Evaluation of the ONCORAL Program for Ambulatory Patients Under Oral Anticancer Drugs Versus Usual Care
Economic impact of cancer treatments is increasing for years: increase of number of patients (385 000 new occurrences in 2015), increase of life expectancies, chronicization of diseases and increase of therapeutic innovation…
- Trial name
- ONCORAL-PRME (NCT03660670)
- Testing
- ONCORAL therapeutic education, Standard of care
- Where
- France
- Volunteers
- 215 people
- Sponsor
- Hospices Civils de Lyon
Crohn's Disease
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately…
- Trial name
- NCT06233461
- Testing
- TAK-279
- Where
- 201 sites in United States, Australia and 23 more
- Volunteers
- 268 people
- Sponsor
- Takeda
Oropharynx Cancer, Squamous Cell Carcinoma of the Oral Cavity
TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer
A combination therapy of Docetaxel, Cisplatin und 5-Fluorouracil (= TPF) will be used in patients with resectable oropharyngeal and cavity of the mouth cancer.
- Trial name
- NCT01108042
- Testing
- Taxotere, Cisplatin, 5-Fluorouracil (5-FU)
- Where
- 4 sites in Germany
- Volunteers
- 71 people
- Sponsor
- Orlando Guntinas-Lichius, Prof. Dr. med.
Non-Hodgkin's Lymphoma, Multiple Myeloma
PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation
This is an open-label, single-arm, multicentre study conducted in Spain to estimate the effectiveness of palifermin administered at a dose of 60 mg/kg/day IV for 3 consecutive days before the start of the conditioning regimen and…
- Trial name
- NCT00352703
- Testing
- Kepivance (Palifermin)
- Volunteers
- 145 people
- Sponsor
- Swedish Orphan Biovitrum
Nausea and Vomiting, Chemotherapy-Induced
A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults
Casopitant may affect liver enzymes that metabolize ketoconazole. This study is designed to test the safety and the extent of the Casopitant affect on ketoconazole levels in healthy human subjects.
- Trial name
- NCT00460707
- Testing
- Casopitant 150 mg, Ketoconazole, Casopitant 50 mg
- Where
- 3 sites in United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Arthritis, Rheumatoid
Safety and Efficacy of TAK-715 in Subjects With Rheumatoid Arthritis
The purpose of this study is to evaluate the safety and efficacy of TAK-715, twice daily (BID), in the treatment of rheumatoid arthritis signs and symptoms in patients with a partial response to methotrexate.
- Trial name
- NCT00760864
- Testing
- TAK-715 and methotrexate, Methotrexate
- Volunteers
- 432 people
- Sponsor
- Takeda
Ovarian Cancer
Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005051
- Testing
- carboplatin, cisplatin, paclitaxel
- Where
- 10 sites in United States
- Sponsor
- NYU Langone Health
Non Small Cell Lung Cancer
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
The purpose of the study is to determine whether the combination of talactoferrin, carboplatin and paclitaxel improves progression free survival and overall survival in patients with non-small cell lung cancer compared to the…
- Trial name
- FORTIS-C (NCT00706862)
- Testing
- Talactoferrin
- Where
- 6 sites in United States
- Volunteers
- 1,100 people
- Sponsor
- Agennix
Cancer, Quality of Life
The Effect of an Oral Supplement,TK3 (Tryptophan and Thiamine) on the Quality of Life and Chemotherapy Tolerance in Cancer Patients With Advanced Disease.
The product under investigation relates to a pharmaceutical composition containing a pyrimidine nitrogen base, thymine, and the essential amino acid tryptophan.
- Conditions
- Cancer, Quality of Life, Chemotherapy Effect, Tryptophan
- Trial name
- TK3bFIIABC (NCT03341286)
- Testing
- TK3
- Where
- Brazil
- Volunteers
- 140 people
- Sponsor
- Faculdade de Medicina do ABC
Intestinal Permeability, Gastrointestinal Irritation
The Effects of Probiotics on Intestinal Permeability in Gastrointestinal Cancer Patients in Chemotherapy
The aim of this study is to test the hypothesis that adjuvant administration of probiotics in cancer patients undergoing chemotherapy can reduce a chemo-induced increased intestinal permeability.
- Conditions
- Intestinal Permeability, Gastrointestinal Irritation, Mucositis
- Trial name
- NCT03704727
- Testing
- Probiotic
- Where
- Denmark
- Volunteers
- 5 people
- Sponsor
- University of Copenhagen
Carcinoma, Squamous Cell, Head and Neck Neoplasms
Monitoring of Oral Human Papillomavirus Infection (HPV) in HPV-positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)
The purpose of this research study is to determine whether and when patients with human papilloma virus positive squamous cell cancer of the oropharynx treated with radiation and chemotherapy clear their human papilloma virus…
- Conditions
- Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
- Trial name
- NCT02045186
- Testing
- Assessment of Oral HPV Infection
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Gastric Cancer Stage IV, Peritoneal Metastases
Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis
In this phase 2 study, we combined sintilimab, paclitaxel and S-1 as regimen to treat gastric cancer patients with peritoneal metastasis. We are aim to estimate the efficacy and safety of this regimen in the phase 2 study.
- Trial name
- NCT05204173
- Testing
- sintilimab, paclitaxel and S-1
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital